Evidence map›Paper›PMID 23530503›Full record

ReviewCurrent pharmaceutical design2014

Differential network analysis in human cancer research.

Ryan Gill, Somnath Datta, Susmita Datta

Abstract readReview
In one paragraph

Review in Current pharmaceutical design, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ryan Gill
Somnath Datta
Susmita DattaDepartment of Bioinformatics and Biostatistics, University of Louisville, Louisville, KY, 40202, USA. susmita.datta@louisville.edu.

Funding

Identification of Proteins from Mass Spectrometry Data: A Statistical ApproachR15CA170091 · NCI · UNIVERSITY OF LOUISVILLE · PI KONG, MAIYING · 2013 to 2013
$464k
Development of Statistical Methods for Analyzing Proteomic Cancer DataR15CA133844 · NCI · UNIVERSITY OF LOUISVILLE · PI DATTA, SUSMITA · 2009 to 2009
$222k
NCI NIH HHS CA133844NCI NIH HHS R15 CA133844NCI NIH HHS R15 CA170091
6 · The paper itself

Abstract

A complex disease like cancer is hardly caused by one gene or one protein singly. It is usually caused by the perturbation of the network formed by several genes or proteins. In the last decade several research teams have attempted to construct interaction maps of genes and proteins either experimentally or reverse engineer interaction maps using computational techniques. These networks were usually created under a certain condition such as an environmental condition, a particular disease, or a specific tissue type. Lately, however, there has been greater emphasis on finding the differential structure of the existing network topology under a novel condition or disease status to elucidate the perturbation in a biological system. In this review/tutorial article we briefly mention some of the research done in this area; we mainly illustrate the computational/statistical methods developed by our team in recent years for differential network analysis using publicly available gene expression data collected from a well known cancer study. This data includes a group of patients with acute lymphoblastic leukemia and a group with acute myeloid leukemia. In particular, we describe the statistical tests to detect the change in the network topology based on connectivity scores which measure the association or interaction between pairs of genes. The tests under various scores are applied to this data set to perform a differential network analysis on gene expression for human leukemia. We believe that, in the future, differential network analysis will be a standard way to view the changes in gene expression and protein expression data globally and these types of tests could be useful in analyzing the complex differential signatures.

Indexed as

Biomedical ResearchLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-LymphomaComputational BiologyHumansModels, Theoretical

Identifiers

PMID23530503
PMCPMC4868626

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.